(Q56386710)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

review article

1 reference

title

Generalised anxiety disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

0 references

1 reference

Peter Tyrer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

David Baldwin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

language of work or name

English

0 references

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

2156-2166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

9553

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

DELINEATION OF TWO DRUG-RESPONSIVE ANXIETY SYNDROMES

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Comorbidity or consanguinity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Generalized Anxiety Disorder and major depressive disorder comorbidity in the National Survey of Mental Health and Well-Being.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Functional health status, chronic medical conditions and disorders of mood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

1 reference

7 January 2021

The empirical basis of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

DSM-III generalized anxiety disorder: an empirical investigation of more stringent criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Delimitation of generalized anxiety disorder: clinical comparisons with panic and major depressive disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Prevalence and service implications of health anxiety in genitourinary medicine clinics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Symptom differences in major depression, dysthymia, panic disorder, and generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Obsessive-compulsive syndromes and disorders: significance of comorbidity with bipolar and anxiety syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Comorbidity of generalized social anxiety disorder and depression in a pediatric primary care sample

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Comorbidity of anxiety disorders with anorexia and bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Exclusion criteria of DSM-III. A study of co-occurrence of hierarchy-free syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Generalized anxiety disorder in patients with major depression: is DSM-IV's hierarchy correct?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The validity of the Hospital Anxiety and Depression Scale. An updated literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Development and validation of the Penn State Worry Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Preliminary reliability and validity of the generalized anxiety disorder questionnaire-IV: A revised self-report diagnostic measure of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

A follow-up study of cognitive bias in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super-family.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

GABA(A) receptor subtypes as targets for neuropsychiatric drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Blunted growth hormone response to clonidine in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Major depression and generalized anxiety disorder. Same genes, (partly) different environments?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Differences in the use of psychiatric outpatient services between the United States and Ontario.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Factors predicting the clinical course of generalised anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The case for cothymia: mixed anxiety and depression as a single diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The National Psychiatric Morbidity surveys of Great Britain--initial findings from the household survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Negative affectivity: the disposition to experience aversive emotional states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The Core Elements of Neurosis: Mixed Anxiety-Depression (Cothymia) and Personality Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Personality and comorbidity of common psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The epidemiology of generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Quality of life in individuals with anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Stability as a distinction between Axis I and Axis II disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The relationship of hypochondriasis to anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Psychiatric comorbidity in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Excess mortality of mental disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The economic burden of anxiety disorders in the 1990s.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The Nottingham study of neurotic disorder: predictors of 12 year costs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Evidence-based pharmacotherapy of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Long-term Treatment of Anxiety and Risk of Withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Gradual withdrawal of diazepam after long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The Nottingham study of neurotic disorder: comparison of drug and psychological treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

A three-year follow-up of psychiatric morbidity in urban and rural primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Current status of beta-blocking drugs in the treatment of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Diazepam, propranolol and their combination in the management of chronic anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Benzodiazepine withdrawal symptoms and propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Clinical aspects of chronic use of alprazolam and lorazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Sequential treatment of mood and anxiety disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The Nottingham Study of Neurotic Disorder: influence of cognitive therapists on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Does cognitive-behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8–14 year follow-up of two clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Prediction of outcome in neurotic disorder: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Cognitive therapy vs behaviour therapy in the treatment of chronic general anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Efficacy of self-help manuals for anxiety disorders in primary care: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Pragmatic evaluation of computer-aided self-help for anxiety and depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Toward a definition of generalized anxiety disorder as an anxious temperament type.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

TEMPS-A: validation of a short version of a self-rated instrument designed to measure variations in temperament

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The relationship between social functioning and psychiatric symptomatology in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Meeting the unmet need for depression services with psycho-educational self-confidence workshops: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The natural history of neurotic disorder in an elderly urban population. Findings from the Liverpool longitudinal study of continuing health in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Change in personality status in neurotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

The twelve-month outcome of patients with neurotic illness in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Placebo response in anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Social phobia: Axis I and II correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Generalized social phobia versus avoidant personality disorder: a commentary on three studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969865-6

7 January 2021

10.1016/S0140-6736(06)69865-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17174708%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference